Fact-checked by Grok 2 weeks ago

Neoplasm

A neoplasm is an abnormal mass of tissue that forms when cells grow and divide more than they should or fail to die when they should, resulting from uncontrolled cellular proliferation known as neoplasia.^[1] These growths, also referred to as tumors, can occur in any part of the body and arise from disruptions in the normal processes of cell replacement and regulation.^[2] Neoplasms are broadly classified into two main types: benign and malignant.^[3] Benign neoplasms are noncancerous, typically grow slowly, remain localized without invading surrounding tissues, and do not spread to other parts of the body; examples include lipomas (fatty tissue growths) and adenomas (glandular growths).^[2] Although generally not life-threatening, they may require treatment if they cause symptoms by pressing on nearby structures or organs.^[2] In contrast, malignant neoplasms are cancerous, exhibit rapid and uncontrolled growth, invade adjacent tissues, and can metastasize to distant sites via the bloodstream or lymphatic system, making them potentially lethal depending on their type, location, and stage.^[1]^[4] Malignant neoplasms, or cancers, are further subclassified based on the tissue of origin and cell type, including carcinomas (arising from epithelial cells, accounting for about 90% of cases, such as those in the breast, lung, or colon), sarcomas (from connective tissues like bone or muscle), leukemias (blood-forming cells in bone marrow), lymphomas (lymphatic system), and myelomas (plasma cells).^[4] The development of neoplasms often involves genetic mutations that impair cell cycle control, though specific causes vary and include risk factors such as tobacco use, radiation exposure, certain infections, obesity, and inherited predispositions.^[5] Diagnosis typically involves imaging, biopsies, and laboratory tests, while treatment options range from surgical removal and radiation for localized growths to chemotherapy and targeted therapies for advanced cases.^[4]

Overview

Definition

A neoplasm (/niːˈoʊplæzəm/) is an abnormal mass of tissue that forms when cells grow and divide more than they should or do not die when they should, resulting from neoplasia, the process of new, uncontrolled cell proliferation that does not serve a physiological purpose.^[1] The term derives from the Ancient Greek words néos ('new') and plásma ('formation, creation'), reflecting its characterization as a novel tissue growth distinct from surrounding normal structures.^[6] Unlike physiological adaptations such as hyperplasia, which involves an increase in cell number in response to a stimulus and is reversible upon removal of that stimulus, or hypertrophy, an increase in cell size due to enhanced functional demand that also regresses when the demand ceases, neoplasms exhibit autonomous, unregulated growth that persists independently of any external trigger.^[7] This irreversible proliferation distinguishes neoplastic tissue from adaptive responses, as the growth continues even after the initiating stimulus is eliminated.^[8] The term "neoplasm" was coined in 1864 by German anatomist Karl Friedrich Burdach to describe non-inflammatory tissue masses arising from disordered cell growth, marking a shift in medical understanding toward cellular pathology.^[9] A hallmark of neoplastic growth is its clonality, wherein the abnormal cells originate from a single progenitor cell that has acquired heritable changes enabling uncontrolled expansion.^[6]

General Characteristics

Neoplasms are characterized by the autonomy of their cells, which proliferate and expand independently of normal host regulatory signals, often forming a discrete mass of tissue known as a tumor that can compress or infiltrate adjacent structures.^[10] This uncontrolled growth distinguishes neoplastic cells from normal tissues, as they evade typical growth constraints and exhibit metabolic independence, such as increased glucose uptake to support their proliferation.^[10] The resulting tumor may remain localized or expand progressively, exerting mechanical pressure on surrounding organs and tissues.^[11] At the cellular level, neoplasms typically arise from a monoclonal origin, where a single progenitor cell gives rise to the entire population, unifying their behavior through shared genetic alterations.^[5] Neoplastic cells display atypical morphology, including an enlarged nucleus with irregular shape, prominent nucleoli, and a high nuclear-to-cytoplasmic ratio, alongside frequent and often abnormal mitotic figures that reflect their dysregulated division.^[10] These features are hallmarks observed across various neoplasms, aiding in their microscopic identification. Neoplasms possess the potential for progression, remaining stable as benign entities or evolving toward malignancy, which introduces the capacity for invasion and distant metastasis.^[5] While benign forms are generally non-invasive and self-limited, malignant neoplasms can disseminate via lymphatic or hematogenous routes, altering their clinical trajectory.^[11] This spectrum underscores the dynamic nature of neoplastic development. Clinically, neoplasms can produce local effects such as tissue obstruction, organ dysfunction, or bleeding due to mass expansion, as seen in gastrointestinal tumors causing bowel blockage.^[12] Functional neoplasms, particularly those arising in endocrine tissues, may secrete excess hormones, leading to systemic imbalances like hyperthyroidism from thyroid adenomas or carcinoid syndrome with flushing and diarrhea.^[13]^[14] These impacts vary by location and type but commonly contribute to morbidity through direct compression or paraneoplastic phenomena.

Classification

Clonality

Neoplasms are characterized by their monoclonal origin, arising from a single progenitor cell that acquires somatic mutations, resulting in a population of genetically identical daughter cells with altered proliferative capacity. This clonal expansion distinguishes neoplasms from normal tissue regeneration or reactive hyperplasias, which involve multiple progenitor cells. The concept of monoclonality underscores the neoplastic process as a Darwinian evolution within the tumor, where the founding clone propagates and may give rise to subclones through further mutations.^[15] Clonality is demonstrated through various molecular techniques that reveal the uniform genetic makeup of neoplastic cells. In females heterozygous for X-linked markers, X-chromosome inactivation assays, such as those analyzing methylation patterns at the human androgen receptor (HUMARA) locus, show a single active allele in tumor cells, indicating derivation from one progenitor. Similarly, glucose-6-phosphate dehydrogenase (G6PD) isoenzyme analysis in heterozygous individuals demonstrates expression of only one enzyme variant (e.g., type A or B) in tumor tissue, as pioneered in studies of chronic myelocytic leukemia where all leukemic cells expressed a single G6PD type despite the patient's heterozygosity. In lymphoid neoplasms, particularly B-cell lymphomas, clonality is confirmed by detecting rearranged immunoglobulin genes via polymerase chain reaction (PCR) or Southern blotting, revealing a dominant rearrangement pattern absent in polyclonal reactive lymphoid populations.^[16]^[17]^[18] Although most neoplasms are monoclonal, rare exceptions include polyclonal proliferations associated with certain viral infections, such as Epstein-Barr virus (EBV)-driven lymphoproliferations in immunocompromised patients, which may mimic neoplasia but lack true autonomous growth and often regress with immune reconstitution. These cases highlight that polyclonality typically signifies a reactive process rather than a neoplastic one, as autonomous neoplasms require the stable genetic alterations of a founding clone.^[19] The assessment of clonality has critical diagnostic implications, enabling differentiation between neoplastic and reactive proliferations; for instance, monoclonal patterns in lymphoid tissues confirm lymphoma over inflammatory conditions like reactive lymphadenitis, guiding therapeutic decisions. Polyclonal growths, by contrast, lack the neoplastic potential for invasion or metastasis, emphasizing clonality as a hallmark of the neoplastic process. Seminal studies using G6PD markers in heterozygous females have provided enduring evidence, showing that even histologically diverse tumors, such as those in the uterus, express a single isoenzyme type, supporting their clonal origin from a single cell.^[19]^[17]

Benign Neoplasms

Benign neoplasms, also known as benign tumors, are abnormal growths composed of cells that multiply excessively but remain noncancerous and do not spread to other parts of the body.^[20] These tumors typically exhibit slow growth rates and are often encapsulated by a fibrous capsule that confines them to a specific location, preventing local invasion of surrounding tissues.^[10] As a result, they remain localized and are frequently curable through surgical excision, with low recurrence rates following complete removal.^[20] Histologically, benign neoplasms consist of well-differentiated cells that closely resemble the normal tissue from which they originate, maintaining organized architecture and function.^[10] They display low mitotic activity, with rare and typical mitotic figures, and lack areas of necrosis due to adequate vascular supply supporting their slow expansion.^[10] This contrasts with more aggressive growths, as benign tumors expand by pushing against adjacent structures rather than infiltrating them.^[10] Common examples of benign neoplasms include lipomas, which arise from adipose (fatty) tissue and present as soft, subcutaneous masses; leiomyomas, such as uterine fibroids, originating from smooth muscle; adenomas, glandular tumors like those in the thyroid or colon; and nevi, commonly known as moles, which are melanocytic proliferations on the skin.^[20] These examples illustrate the diverse tissue origins of benign growths, which can occur in nearly any organ system.^[20] Clinically, benign neoplasms are usually asymptomatic and discovered incidentally during imaging or examinations, though larger ones may exert a mass effect by compressing nearby nerves, blood vessels, or organs, leading to symptoms such as pain, obstruction, or functional impairment.^[20] For instance, a sizable uterine leiomyoma can cause pelvic pressure or heavy menstrual bleeding, while a brain meningioma might induce headaches or neurological deficits through compression.^[20] Although generally indolent, certain benign neoplasms carry a rare risk of malignant transformation; villous adenomas of the colon, for example, larger than 1 cm have a high risk of malignancy, with those >2 cm showing a 10-20% risk of containing adenocarcinoma.^[21] Benign neoplasms are far more prevalent than their malignant counterparts, often representing the majority of diagnosed tumors across various sites, such as soft tissues where benign lumps outnumber sarcomas significantly.^[22] Their frequent incidental detection underscores their commonality in the general population, with many remaining undetected throughout life.^[20]

Malignant Neoplasms

Malignant neoplasms, commonly referred to as cancers, are characterized by uncontrolled cellular proliferation that invades surrounding tissues and has the potential for metastasis, the spread of cancer cells to distant sites via lymphatic or hematogenous routes, resulting in multi-organ involvement. Unlike benign neoplasms, which remain localized, malignant tumors exhibit aggressive behavior that disrupts normal tissue architecture and function. Malignant neoplasms are graded based on the degree of cellular differentiation, ranging from Grade 1 (well-differentiated, resembling normal cells) to Grade 4 (undifferentiated or anaplastic, showing little resemblance to the tissue of origin), which helps predict tumor behavior and guide treatment. They are staged using the TNM system, where T describes the primary tumor size and extent, N indicates regional lymph node involvement, and M denotes the presence of distant metastasis, allowing for standardized assessment of disease progression from Stage 0 (in situ) to Stage IV (advanced metastatic disease). The major types of malignant neoplasms include carcinomas, which arise from epithelial tissues and account for 80-90% of all human cancers, such as adenocarcinomas of the lung or breast; sarcomas, originating from mesenchymal tissues like bone or soft tissue; leukemias and lymphomas, which involve hematopoietic and lymphoid cells; and germ cell tumors, typically affecting reproductive or embryonic tissues. These categories reflect the diverse origins of malignant growths and their varying clinical presentations. Key clinical hallmarks of malignant neoplasms encompass anaplasia, marked by loss of cellular differentiation and pleomorphic nuclei; rapid and uncontrolled growth that outpaces blood supply; promotion of angiogenesis to sustain tumor expansion; and systemic effects like cachexia, a wasting syndrome involving severe weight loss, muscle atrophy, and fatigue due to metabolic alterations induced by the tumor. These features contribute to the high morbidity and mortality associated with cancers, which remain the leading cause of death globally, responsible for approximately 10 million deaths annually as of 2020 data updated through 2023.

Causes

Genetic Factors

Genetic factors play a central role in the development of neoplasms through both inherited germline mutations and acquired somatic alterations that disrupt normal cellular regulation. Proto-oncogenes, which encode proteins involved in cell growth and division, can be activated by mutations to become oncogenes, promoting uncontrolled proliferation. For instance, point mutations in the RAS gene family, particularly at codons 12, 13, or 61, lock the RAS protein in a constitutively active state, leading to persistent downstream signaling that drives tumorigenesis in various cancers, including pancreatic and colorectal carcinomas.^[23] Similarly, chromosomal translocations can fuse genes to create potent oncogenes, such as the BCR-ABL fusion resulting from the t(9;22) translocation in chronic myeloid leukemia, which produces a chimeric tyrosine kinase that constitutively activates signaling pathways essential for leukemic cell survival and expansion.^[24] Tumor suppressor genes, conversely, normally inhibit cell growth and promote DNA repair or apoptosis; their inactivation contributes to neoplasm formation by removing these brakes. Alfred Knudson's two-hit hypothesis, formulated based on retinoblastoma incidence patterns, posits that both alleles of a tumor suppressor gene must be inactivated for tumor development: one germline mutation inherited in hereditary cases and a somatic "second hit" in the other allele, or two somatic hits in sporadic cases.^[25] This model was exemplified by mutations in the RB1 gene, where biallelic loss leads to retinoblastoma by derepressing E2F transcription factors and promoting uncontrolled cell cycle progression.^[25] Inherited genetic syndromes arise from germline mutations in tumor suppressor genes, conferring high lifetime cancer risks. Li-Fraumeni syndrome, caused by heterozygous TP53 mutations, predisposes individuals to a broad spectrum of cancers, including sarcomas, breast cancer, brain tumors, and leukemias, with nearly a 100% lifetime cancer risk for females and about 90% cumulative risk by age 60 overall.^[26] Mutations in BRCA1 and BRCA2 genes increase the risk of hereditary breast and ovarian cancer, with BRCA1 carriers having a 55-72% lifetime breast cancer risk and 39-46% ovarian cancer risk, while BRCA2 carriers face 45-69% and 10-27% risks, respectively, due to impaired DNA double-strand break repair.^[27] Familial adenomatous polyposis results from APC gene mutations, leading to hundreds of colorectal polyps and nearly 100% risk of colorectal cancer by age 40 if untreated, as APC normally regulates Wnt signaling to prevent polyp formation.^[28] Most neoplasms arise from somatic mutations accumulated over time in non-inherited cells, following a multistep carcinogenesis process. In colorectal cancer, Bert Vogelstein's model describes sequential somatic alterations: early APC inactivation initiates adenoma formation, followed by KRAS activation for growth, and late TP53 loss enabling invasion and metastasis, illustrating how these genetic hits progressively transform normal epithelium into carcinoma.^[29] Approximately 5-10% of all cancers are hereditary, stemming from germline mutations, while the vast majority are sporadic, driven by somatic changes.^[30] These genetic alterations contribute to the clonal expansion characteristic of neoplasms by conferring selective growth advantages to mutated cells.

Environmental Factors

Environmental factors play a significant role in neoplasm development, encompassing a range of external exposures that can initiate or promote cellular changes leading to uncontrolled growth. These modifiable risks include chemical agents, physical stressors, infectious pathogens, lifestyle choices, and occupational hazards, collectively accounting for a substantial portion of preventable cancers worldwide. Unlike inherent genetic predispositions, environmental influences often interact with genetic factors to elevate overall risk, but their impact can be mitigated through avoidance and public health interventions. Chemical carcinogens, such as those in tobacco smoke, are among the most potent environmental contributors to neoplasms. Tobacco smoke contains polycyclic aromatic hydrocarbons and other toxins that damage lung tissue, with approximately 85% of lung cancer cases attributable to smoking.^[31] Asbestos fibers, another key chemical agent, are strongly linked to mesothelioma, a rare cancer of the lung lining, following prolonged inhalation in contaminated environments.^[32] Physical agents like ionizing radiation and ultraviolet (UV) radiation also drive neoplasm formation through direct cellular disruption. Exposure to ionizing radiation, as experienced by atomic bomb survivors in Hiroshima and Nagasaki, significantly increases leukemia risk, with studies showing a dose-dependent elevation in incidence rates peaking years after exposure.^[33] UV radiation from sunlight induces pyrimidine dimers in skin DNA, contributing to the majority of melanoma cases, particularly in fair-skinned populations with high sun exposure.^[34] Infectious agents are responsible for about 13% of the global cancer burden as of 2018, highlighting the role of pathogens in oncogenesis.^[35] Human papillomavirus (HPV) infection causes nearly all cervical cancers, while hepatitis B virus (HBV) and hepatitis C virus (HCV) account for over 70% of hepatocellular carcinomas through chronic liver inflammation. Helicobacter pylori bacteria, a common gastric pathogen, is associated with approximately 90% of non-cardia gastric cancers. Lifestyle factors further amplify environmental risks, with dietary patterns, alcohol consumption, and obesity serving as key modifiable contributors. High-fat, low-fiber diets are linked to increased colorectal cancer incidence via altered gut microbiota and inflammation, while excessive alcohol intake elevates risks for esophageal and liver cancers through acetaldehyde production and cirrhosis. Obesity, often driven by caloric excess, promotes endometrial and postmenopausal breast cancers via elevated estrogen and insulin levels.^[36] Occupational exposures represent targeted environmental hazards, particularly in industrial settings. Benzene, a solvent used in manufacturing, is a known cause of acute myeloid leukemia following chronic inhalation or skin contact. Arsenic, encountered in mining and pesticide production, heightens risks for skin and lung cancers, with groundwater contamination also posing widespread threats in certain regions.

Pathophysiology

DNA Damage

DNA damage represents a fundamental initiator of neoplastic transformation, arising from both endogenous and exogenous sources that compromise genomic integrity. Endogenous damage includes base modifications such as oxidation and alkylation, single-strand breaks, and spontaneous hydrolysis, often generated by reactive oxygen species (ROS) during normal cellular metabolism.^[37] Exogenous insults, such as ultraviolet (UV) radiation or ionizing radiation, induce bulky adducts, strand breaks, and inter- and intrastrand crosslinks that distort the DNA helix.^[38] These lesions, if unrepaired, can lead to mutations that disrupt cellular homeostasis and promote oncogenesis.^[39] Cells employ specialized DNA repair pathways to counteract these threats and maintain genome stability. Base excision repair (BER) addresses small, non-helix-distorting lesions like oxidized or alkylated bases by excising the damaged nucleotide and replacing it via DNA polymerase activity.^[38] Nucleotide excision repair (NER) targets bulky, helix-distorting adducts, such as those formed by UV-induced cyclobutane pyrimidine dimers, through recognition, excision, and resynthesis; defects in NER, as seen in xeroderma pigmentosum, confer a greater than 10,000-fold increased risk of non-melanoma skin cancers due to unchecked accumulation of photoproducts.^[40] Mismatch repair (MMR) corrects base-base mismatches and insertion/deletion loops arising during DNA replication; germline MMR defects underlie Lynch syndrome, substantially elevating lifetime risks for colorectal, endometrial, and other cancers through microsatellite instability.^[41] Persistent DNA damage evading repair contributes to the hallmarks of cancer by fostering somatic mutations in key regulatory genes. Unresolved lesions during replication can cause nucleotide substitutions, including characteristic UV-induced C>T transitions at dipyrimidine sites, which are prevalent in melanoma driver mutations such as those in BRAF and NRAS.^[42] These mutations activate oncogenes or inactivate tumor suppressors like TP53, enabling uncontrolled proliferation and survival advantages.^[38] Additionally, failures in cell cycle checkpoints exacerbate this process; the G1/S checkpoint, mediated by ATM/ATR signaling, halts progression to allow repair of single-strand breaks, while the G2/M checkpoint prevents mitosis in the presence of double-strand breaks, but their dysfunction permits damaged cells to divide, amplifying mutational load.^[43] Therapeutically, neoplasms' reliance on imperfect DNA repair is exploited by DNA-damaging chemotherapeutics. Agents like cisplatin form intrastrand and interstrand crosslinks that stall replication forks and trigger apoptosis in rapidly dividing cancer cells, achieving high efficacy in treating testicular, ovarian, and lung cancers by overwhelming repair capacity.^[44] This vulnerability underscores DNA damage as both a driver and a target in neoplastic progression.^[45]

Field Defects

Field defects, also known as field cancerization, refer to multifocal regions of genetically altered cells within apparently normal tissue that predispose to the development of multiple neoplasms, often arising from shared early mutagenic events such as chronic exposure to carcinogens.^[46] This concept was first described in 1953 in the context of oral squamous cell carcinomas, where atypical epithelial changes were observed in clinically normal mucosa surrounding tumors, suggesting a lateral spread of premalignant alterations. These fields represent patchy areas of mutated cell clones that have undergone selective expansion but lack the full transformative changes required for overt malignancy.^[46] At the molecular level, field defects involve the accumulation of low-level somatic mutations and epigenetic changes, such as TP53 alterations, without progression to invasive cancer, creating a primed tissue environment vulnerable to further oncogenic hits.^[46] For instance, in head and neck squamous cell carcinomas associated with tobacco exposure, clonal TP53 mutations are detected in normal-appearing epithelium adjacent to tumors, contributing to the risk of synchronous or metachronous lesions. Similarly, in Barrett's esophagus, low-frequency TP53 mutations in metaplastic epithelium serve as a field defect predisposing to esophageal adenocarcinoma. Other examples include actinic keratosis in sun-exposed skin, where p53-mutated keratinocyte clones form fields that progress to cutaneous squamous cell carcinoma, and the colonic mucosa in familial adenomatous polyposis (FAP), where germline APC mutations create widespread polypoid fields prone to colorectal cancer development.^[46] Detection of field defects relies on molecular analysis of biopsies from surrounding tissue, including assessment of loss of heterozygosity (LOH) at key loci like 17p13 (TP53) or 9p21, and epigenetic markers such as promoter hypermethylation patterns (e.g., MGMT or APC).^[47] In head and neck cancers, LOH analysis has identified clonal fields in over 60% of cases with recurrent disease, while methylation profiling in colorectal mucosa detects field alterations up to 10 cm from tumors.^[47]^[48] Clinically, field defects explain elevated rates of local recurrence and multiple primary tumors, necessitating wider surgical margins or field-directed therapies like topical chemoprevention to eradicate subclinical lesions.^[47] In skin cancers, recognizing actinic fields guides photodynamic therapy to reduce squamous cell carcinoma incidence, while in FAP, prophylactic colectomy addresses the entire colonic field to prevent inevitable progression.^[46] This understanding enhances risk stratification and surveillance strategies for at-risk tissues.^[46]

Genome Instability

Genome instability in neoplasms encompasses the heightened propensity for chromosomal and epigenetic alterations that drive tumor progression, often arising from the accumulation of unrepaired DNA damage in preceding pathophysiological stages. This instability manifests as dynamic changes within tumor cells, promoting heterogeneity and evolutionary adaptation, distinct from static initial lesions.^[49] Chromosomal instability (CIN) is a primary form of genome instability characterized by recurrent errors in chromosome segregation and structure, leading to aneuploidy and structural rearrangements such as translocations. A classic example is the Philadelphia chromosome, a t(9;22) translocation resulting in the BCR-ABL fusion gene that drives chronic myeloid leukemia (CML).^[50] CIN contributes to the malignant phenotype by generating diverse karyotypes that enhance tumor adaptability.^[51] Microsatellite instability (MSI) represents another key type, arising from defects in DNA mismatch repair (MMR) proteins, which fail to correct replication errors in repetitive microsatellite sequences, resulting in hypermutable DNA tracts.^[52] This is prominently featured in Lynch syndrome, an autosomal dominant condition caused by germline mutations in MMR genes like MLH1, MSH2, MSH6, or PMS2, predisposing individuals to colorectal and other cancers with high MSI.^[53] MSI-high tumors exhibit a distinct mutational profile that influences immune recognition and therapeutic response. Epigenetic instability involves aberrant modifications that alter gene expression without changing the DNA sequence, including hypermethylation of promoter CpG islands that silences tumor suppressor genes. For instance, hypermethylation of the MLH1 promoter leads to MMR deficiency and MSI in sporadic colorectal cancers.^[54] Additionally, dysregulated histone modifications, such as altered acetylation or methylation patterns, contribute to chromatin remodeling that favors oncogenic states and genomic instability.^[55] Key drivers of genome instability include telomere dysfunction, where critically short telomeres lose protective function, prompting end-to-end chromosomal fusions and breakage-fusion-bridge cycles that amplify rearrangements.^[56] Centrosome amplification, often triggered by oncogenic signaling, disrupts mitotic spindle assembly, leading to multipolar mitoses and unequal chromosome distribution.^[57] These mechanisms perpetuate a cycle of ongoing genomic alterations within the tumor.^[58] Genome instability fuels Darwinian evolution in neoplasms by generating variant subclones, with selective pressures favoring aggressive phenotypes that evade therapy and metastasize.^[59] In breast cancer, elevated CIN correlates with poor prognosis, as it promotes intratumor heterogeneity and resistance to treatment.^[49] This evolutionary dynamic underscores instability's role in transitioning from benign to malignant states.^[60] Recent advances in single-cell sequencing, as of 2025, have illuminated how genome instability drives intratumor heterogeneity, revealing subclonal variations in copy number alterations and mutational burdens that underpin tumor adaptability.^[61] For example, in breast cancer, single-cell RNA sequencing has shown that metastatic lesions exhibit heightened chromosomal instability signatures, correlating with increased heterogeneity and worse outcomes.^[61] These insights highlight the spatial and temporal dynamics of instability in neoplasm progression.^[62]

Terminology

Etymology

The term neoplasm derives from the Greek roots neo- meaning "new" and plasma meaning "formation" or "mold," literally translating to "new formation."^[9] This etymology emphasizes the concept of an autonomous tissue growth arising independently of normal physiological processes.^[63] The word was first coined in 1864 by the German anatomist and physiologist Karl Friedrich Burdach to describe a pathological new growth distinct from the surrounding tissues, marking a precise linguistic distinction in medical terminology.^[9] It was subsequently popularized in the mid-19th century following Rudolf Virchow's advancement of cellular pathology; his 1858 work Die Cellularpathologie framed abnormal growths as arising from disordered cellular proliferation rather than simple inflammatory swellings, contributing to the conceptual framework for terms like "neoplasm" and differentiating them from the broader Latin-derived term "tumor" (meaning "swelling").^[64]^[65] The related term neoplasia, denoting the abnormal process of new tissue formation, entered medical literature around 1871, further refining the conceptual framework for understanding uncontrolled growth.^[66] Overall, the adoption of "neoplasm" and its variants reflects the pivotal 19th-century transition from ancient humoral theories of disease—viewing imbalances in bodily fluids as the root of pathology—to Virchow's revolutionary cellular paradigm, which grounded disease in microscopic tissue changes.^[65]^[64]

Neoplasm vs. Tumor

In medical contexts, the terms "neoplasm" and "tumor" are often employed synonymously to describe abnormal tissue growths, especially palpable masses, though "tumor" traditionally denotes any localized swelling, including non-neoplastic examples such as abscesses formed by inflammatory processes.^[7] A neoplasm, by contrast, specifically indicates an abnormal proliferation of cells driven by neoplastic changes in cellular regulation, distinguishing it from mere swellings caused by inflammation, trauma, or other reactive processes.^[2] This distinction clarifies that while all neoplasms have the potential to manifest as tumors when they aggregate into a discrete mass, not all tumors qualify as neoplasms; for example, a hematoma—a localized collection of extravasated blood following injury—forms a swelling classified as a tumor but arises from vascular disruption rather than neoplastic cell growth.^[67] Likewise, an abscess, characterized by pus accumulation due to bacterial infection and immune response, represents an inflammatory tumor without the uncontrolled cellular replication inherent to neoplasms.^[68] In oncology practice, "tumor" is predominantly reserved for solid, localized growths, such as carcinomas of the lung or brain tumors, whereas "neoplasm" encompasses a broader spectrum, including non-solid forms like leukemia, a hematopoietic neoplasm involving widespread abnormal proliferation in the blood and bone marrow without forming a distinct tumor mass.^[2]^[69] The term "tumor" originated in ancient medicine as one of the four cardinal signs of inflammation—tumor (swelling), rubor (redness), calor (heat), and dolor (pain)—as articulated by the Roman physician Aulus Cornelius Celsus around 25 AD, reflecting its initial association with any inflammatory response rather than specifically neoplastic pathology.^[70] By the 19th century, pathological advancements, including microscopic examination of tissues, shifted its primary usage toward neoplastic contexts, reserving the broader sense of swelling for descriptive rather than diagnostic purposes.^[71] Among the general public, a prevalent misconception equates "tumor" directly with cancer, overlooking that tumors include both benign (non-invasive) and malignant (invasive) neoplasms, as well as entirely non-neoplastic swellings, with only the malignant subset representing cancerous growth.^[2]

References

[1]
Definition of neoplasm - NCI Dictionary of Cancer Terms
An abnormal mass of tissue that forms when cells grow and divide more than they should or do not die when they should. Neoplasms may be benign (not cancer) ...
[2]
What Are Neoplasms and Tumors? - American Cancer Society
Mar 31, 2025 · A neoplasm is an abnormal growth of cells in the body. It happens when the body's normal process of making and replacing cells doesn't work as it should.
[3]
Tumor (Neoplasm): Types, Symptoms & Treatment - Cleveland Clinic
A tumor, or neoplasm, is a mass of abnormal cells that form in your body. Tumors can affect tissues, glands, organs, skin and bone. They can be big or small.
[4]
Malignant Neoplasm: What It Is, Types & Factors - Cleveland Clinic
Feb 2, 2022 · A neoplasm is an abnormal growth of tissue that can be benign (noncancerous) or malignant (cancerous). Benign tumors (noncancerous neoplasms) ...
[5]
The Development and Causes of Cancer - The Cell - NCBI Bookshelf
Most cancers fall into one of three main groups: carcinomas, sarcomas, and leukemias or lymphomas. Carcinomas, which include approximately 90% of human cancers ...Types Of Cancer · Causes Of Cancer · Properties Of Cancer Cells
[6]
Neoplasm Definition - News-Medical
Neoplasia refers to a mass that has developed due to abnormal cell or tissue growth. Neoplasia refers to various types of growths including non-cancerous or ...
[7]
Cancer Terms - SEER Training Modules
Hyperplasia, metaplasia, and dysplasia are reversible because they are results of a stimulus. Neoplasia is irreversible because it is autonomous.
[8]
Neoplasms 101: What they are and how they're treated
Jun 10, 2025 · A neoplasm is defined as an abnormal growth of tissue. It forms when cells grow and divide in an unregulated and irreversible manner.
[9]
NEOPLASM Definition & Meaning - Merriam-Webster
Oct 8, 2025 · Etymology. borrowed from German Neoplasma, from neo- neo- + -plasma -plasm (perhaps as Greco-Latin rendering of German Neubildung, ...
[10]
TUMOR CELL MORPHOLOGY - Comparative Oncology - NCBI - NIH
Morphologically, the cancerous cell is characterized by a large nucleus, having an irregular size and shape, the nucleoli are prominent, the cytoplasm is scarce ...THE TUMOR CELL · TUMOR DEVELOPMENT AND... · TUMOR ANGIOGENESIS
[11]
What Is Cancer? - NCI - National Cancer Institute
Oct 11, 2021 · Benign tumors do not spread into, or invade, nearby tissues. When removed, benign tumors usually don't grow back, whereas cancerous tumors ...Cancer Statistics · Common Cancer Myths and · Reuse of NCI Information
[12]
Small Bowel Neoplasms - StatPearls - NCBI Bookshelf
Patients with small bowel adenocarcinoma are often complicated with local tumoral effects, including duodenal obstruction and crampy abdominal pain in duodenal ...Missing: imbalances | Show results with:imbalances
[13]
ENDOCRINE TUMORS - Comparative Oncology - NCBI - NIH
Endocrine gland tumors clinically manifest by hormonal excesses, with signs and biochemical changes characteristic of the affected gland.
[14]
Endocrine Neoplasms of the Gastroenteropancreatic (GEP) System
The diagnosis of carcinoid tumors rests on a strong clinical suspicion in patients who present with flushing, diarrhea, wheezing, myopathy, and right-sided ...
[15]
Clonality Studies in Cancer Based on X Chromosome Inactivation ...
The understanding that human neoplasms are clonal cell proliferations ultimately derived from a single transformed somatic cell represents a major advance ...<|control11|><|separator|>
[16]
X-linked clonality testing: interpretation and limitations - PMC - NIH
The first clonality studies using X-chromosome inactivation were based on G6PD isoenzymes (Figure 2). In the African population, there are 3 main G6PD ...
[17]
Clonal origin of chronic myelocytic leukemia in man - PMC - NIH
Clonal origin of chronic myelocytic leukemia in man. P J Fialkow. P J Fialkow ... glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors.
[18]
The value of detecting immunoglobulin gene rearrangements in the ...
Sep 29, 2017 · Detection of gene rearrangements in immunoglobulin (IG), a specific marker of B lymphocyte clones, is an important method in the diagnosis of B-cell lymphoma.
[19]
Clonal Origin and Expansions in Neoplasms - NIH
Although clonality is considered the hallmark of neoplasms, the distinction between clonal origin and clonal expansion in tumors remains controversial. A priori ...
[20]
Benign Tumor: Definition, Types & Symptoms - Cleveland Clinic
A benign tumor is an abnormal but noncancerous collection of cells. It may not cause symptoms, but a large benign tumor may press on nearby tissue and ...
[21]
Villous Adenoma - StatPearls - NCBI Bookshelf
However, the major concern with villous adenomas is the development of malignancy. Lesions larger than 1 cm have a high risk for malignancy.
[22]
Prevalence of Malignant Soft Tissue Tumors in Extremities - NIH
Because benign soft tissue “lumps” are far more common than malignant ones, the diagnosis of a soft tissue sarcoma may be made after excision of a presumed ...<|control11|><|separator|>
[23]
A comprehensive survey of Ras mutations in cancer - PMC
Ras proteins are proto-oncogenes that are frequently mutated in human cancers. They are encoded by three ubiquitously expressed genes: HRAS, KRAS and NRAS.
[24]
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
The molecular consequence of this translocation is the generation of the BCR-ABL1 oncogene that encodes the chimeric BCR-ABL1 protein with constitutive kinase ...
[25]
Retinoblastoma—A Paradigm for Tumor-Suppressor Gene Function
Knudson's hypothesis served not only to illustrate mechanisms through which inherited and somatic genetic changes might collaborate in tumorigenesis, but it ...
[26]
Definition of Li-Fraumeni syndrome - NCI Dictionary of Cancer Terms
... mutations (changes) in the TP53 gene. Having Li-Fraumeni syndrome increases the risk of developing many types of cancer. Cancers often develop at an early ...
[27]
BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet
Jul 19, 2024 · The risks of developing breast and ovarian cancer are markedly increased in people who inherit a harmful change in BRCA1 or BRCA2.How much does an inherited... · Who should consider genetic...
[28]
Familial adenomatous polyposis - Genetics - MedlinePlus
Aug 26, 2025 · Familial adenomatous polyposis (FAP) is an inherited disorder characterized by a greatly increased risk of colorectal cancer.
[29]
The Landmark Discovery That Paved the Way to a Mechanistic ...
Sep 1, 2021 · This paradigm, now generally referred to as the Vogelstein genetic model of colorectal tumorigenesis, clearly showed that the induction of the ...
[30]
The Genetics of Cancer - NCI
Aug 8, 2024 · Up to 10% of all cancers may be caused by inherited genetic changes. Inheriting a cancer-related genetic change doesn't mean you will definitely ...Is cancer a genetic disease? · Should I get genetic testing for...
[31]
2. Tobacco-attributable cancer burden in the UK in 2010 - Nature
Dec 6, 2011 · For lung cancer (Table 2), the results suggest that about 85% of the lung cancer cases in men are attributable to smoking, and in women the ...
[32]
Ionizing radiation and leukemia mortality among Japanese Atomic ...
This paper provides the first comprehensive report on mortality by type of leukemia among the Japanese atomic bomb survivors in the Life Span Study (LSS).
[33]
Infection - Cancer Atlas
The contribution of each infectious agent to cancer burden varies substantially across different regions (Figure 5.2). Figure 5.2. Proportion (%) of cancers ...
[34]
Alcohol and Cancer Risk Fact Sheet - NCI
May 2, 2025 · Epidemiologic studies have shown that people who drink alcohol are at higher risk of certain cancers than those who do not drink alcohol and ...
[35]
DNA-damage repair; the good, the bad, and the ugly - PMC
Endogenous sources of DNA damage include hydrolysis, oxidation, alkylation, and mismatch of DNA bases; sources for exogenous DNA damage include ionizing ...
[36]
DNA Damage/Repair Management in Cancers - PMC - NIH
Apr 23, 2020 · Sources of DNA damage can be endogenous or exogenous and include reactive oxygen species (ROS) or ionizing radiation [1]. DNA damaging ...
[37]
DNA damage repair: historical perspectives, mechanistic pathways ...
Indeed, when experiencing either endogenous or exogenous stresses, cells can generate various types of DNA damage, including base pair alterations, DNA ...
[38]
Xeroderma Pigmentosum - StatPearls - NCBI Bookshelf
Jul 4, 2023 · Patients with xeroderma pigmentosum have a more than 10000 fold risk of developing non-melanoma skin cancer compared to the general population.
[39]
Mismatch repair defects and Lynch syndrome: the role of the basic ...
This review will examine how the diagnosis, treatment and even prevention of Lynch syndrome-associated cancers has benefitted from extensive basic science ...
[40]
Mechanisms of UV-induced mutations and skin cancer - PMC - NIH
Ultraviolet (UV) irradiation causes various types of DNA damage, which leads to specific mutations and the emergence of skin cancer in humans.
[41]
Cell cycle checkpoints and their inactivation in human cancer - PMC
The DNA damage checkpoint acts at three different stages of the cell cycle, inducing G1 arrest, a block of DNA replication or a G2 delay, depending on the type ...
[42]
The evolving role of DNA inter-strand crosslinks in chemotherapy - NIH
DNA crosslinking agents make up a broad class of chemotherapy agents that target rapidly dividing cancer cells by disrupting DNA synthesis.
[43]
DNA-Damaging Agents in Cancer Chemotherapy - ScienceDirect.com
May 23, 2013 · Indeed, cisplatin therapy can cure over 90% of all testicular cancer cases and also has good efficacy in the treatment of ovarian, bladder, head ...
[44]
An evolutionary perspective on field cancerization - Nature
Dec 8, 2017 · Field cancerization underlies the development of many types of cancer. This Review examines the biological mechanisms that drive the ...Missing: neoplasms | Show results with:neoplasms
[45]
Clinical implications and utility of field cancerization
Mar 15, 2007 · This review examines the concept of field cancerization in several cancers and its possible utility in four areas of oncology.<|control11|><|separator|>
[46]
MGMT Promoter Methylation and Field Defect in Sporadic Colorectal ...
Sep 21, 2005 · Abstract. Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been ...
[47]
The two sides of chromosomal instability: drivers and brakes in cancer
Mar 29, 2024 · Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell malignancy. CIN triggers a chain reaction in cells ...
[48]
European LeukemiaNet laboratory recommendations for the ...
Oct 4, 2023 · Chronic myeloid leukemia (CML) is characterized by the Philadelphia (Ph) chromosome, described in 1960 as the first recurrent chromosome ...
[49]
A pan-cancer compendium of chromosomal instability - Nature
Jun 15, 2022 · Chromosomal instability (CIN) results in the accumulation of large-scale losses, gains and rearrangements of DNA.Missing: review | Show results with:review
[50]
Lynch Syndrome - GeneReviews® - NCBI Bookshelf - NIH
Feb 5, 2004 · Microsatellite instability (MSI) testing showing that tumor tissue is MSI high. ... Pathogenic variants in four of the MMR genes can cause Lynch ...
[51]
Microsatellite instability: a review of what the oncologist should know
Jan 13, 2020 · Lynch syndrome is an autosomal dominant tumor syndrome caused by mutations in MMR strains, and it can also cause tumors in other parts of ...
[52]
Epigenetic gene silencing in cancer: the DNA hypermethylome
One of the best-known lesions of the malignant cell is the transcriptional repression of tumor-suppressor genes by promoter CpG island hypermethylation.Epigenetic Gene Silencing In... · Aging And Cancer: The Case... · Epigenetic Silencing Of...<|separator|>
[53]
Epigenetic modifications in cancer - PMC - NIH
Hypomethylation in tumor cells is primarily caused by the loss of methylation from repetitive regions of the genome and the resulting genomic instability is a ...
[54]
Telomeres, chromosome instability and cancer - Oxford Academic
Loss of telomere function is an important mechanism for the chromosome instability commonly found in cancer.Telomeres, Chromosome... · Telomeres And Their... · Failure Of Telomere Function...<|separator|>
[55]
Mechanisms to suppress multipolar divisions in cancer cells with ...
Jul 28, 2008 · Multiple centrosomes in tumor cells create the potential for multipolar divisions that can lead to aneuploidy and cell death.
[56]
Centrosome Amplification and Cancer: A Question of Sufficiency
Feb 6, 2017 · Centrosome amplification is a common feature of many types of cancer, but whether it is a cause or consequence is hotly debated.
[57]
Cancer evolution: Darwin and beyond - PMC - PubMed Central
While grounded in somatic selection, several lines of evidence suggest a Darwinian model alone is insufficient to fully explain cancer evolution.
[58]
Genome-level selection in tumors as a universal marker of ... - Nature
Jul 16, 2025 · We find that, despite the wide variation across patients, the selection strength on tumor genomes in individual patients is stable and largely ...
[59]
Single-cell RNA sequencing reveals different cellular states ... - Nature
Aug 26, 2025 · Moreover, metastatic tumors demonstrated elevated CNV scores and greater intratumoral heterogeneity, indicative of increased genomic instability ...
[60]
Intratumoral heterogeneity in microsatellite instability at single cell ...
Jul 11, 2025 · We found evidence of intratumoral heterogeneity in MSI both in individuals originally classified as MSI-H and MSS.
[61]
Neoplasm - Etymology, Origin & Meaning
Origin and history of neoplasm "a new growth distinct from the tissue in which it occurs, a true tumor," 1864, coined in Modern Latin by German physiologist ...
[62]
The life and work of Rudolf Virchow 1821–1902: “Cell theory ... - NIH
Aug 19, 2016 · Virchow was the first to correctly link the origin of cancers from otherwise normal cells, believing that cancer is caused by severe irritation in the tissues.
[63]
A Brief History of Cancer | American Cancer Society
Oct 22, 2025 · An Italian doctor named Giovanni Morgagni was a pioneer in the field of pathology. He did the first autopsies in 1761. He described what he saw ...
[64]
NEOPLASIA Definition & Meaning - Merriam-Webster
Sep 9, 2025 · Word History ; Etymology. probably borrowed from French néoplasie, from néo- neo- + -plasie -plasia ; First Known Use. 1871, in the meaning ...
[65]
Soft Tissue Masses | UW Orthopaedic Surgery and Sports Medicine
A hematoma, cyst from arthritis, or swelling from a sprain or strain might be confused with a soft tissue tumor. Causes. The cause of most soft tissue tumors is ...
[66]
Intramural Gastric Abscess Misdiagnosed as Advanced Gastric Cancer
When an abscess directly invades adjacent organs, it can be confused with gastric cancer, gastrointestinal stromal tumors (GISTs), and neuroendocrine neoplasms.
[67]
Acute Lymphocytic Leukemia (ALL): Introduction - UR Medicine
Leukemia cells often don't form tumors. They travel in the blood all over the body. This means leukemia can affect organs anywhere in the body.
[68]
The five cardinal signs of inflammation: Calor, Dolor, Rubor, Tumor ...
The five cardinal signs of inflammation: Calor, Dolor, Rubor, Tumor ... and Penuria (Apologies to Aulus Cornelius Celsus, De medicina, c. A.D. 25)
[69]
Tumor Structure and Tumor Stroma Generation - NCBI - NIH
A tumor (fully evolved) is a population of abnormal cells characterized by temporally unrestricted growth and the ability to grow in at least three different ...Tumor Structure And Tumor... · Tumor Stroma Generation · Steps In Tumor Stroma...<|control11|><|separator|>